Patents Assigned to Capella Therapeutics, Inc.
  • Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
    Patent number: 11787788
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: October 17, 2023
    Assignee: CAPELLA THERAPEUTICS, INC.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 11713322
    Abstract: Provided herein are benzimidazole derivatives, for example, or Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: August 1, 2023
    Assignee: CAPELLA THERAPEUTICS, INC.
    Inventor: Yun Long
  • BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20220298167
    Abstract: Provided herein are benzimidazole derivatives, for example, or Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 22, 2022
    Applicant: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • Benzimidazoles for use in the treatment of cancer and inflammatory diseases
    Patent number: 11427565
    Abstract: Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: August 30, 2022
    Assignee: CAPELLA THERAPEUTICS, INC.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 11242352
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20210061816
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: June 15, 2020
    Publication date: March 4, 2021
    Applicant: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 10683304
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 16, 2020
    Assignee: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 10647707
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: May 12, 2020
    Assignee: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • Benzimidazoles for use in the treatment of cancer and inflammatory diseases
    Patent number: 10590108
    Abstract: Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 17, 2020
    Assignee: CAPELLA THERAPEUTICS, INC.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 10202398
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: February 12, 2019
    Assignee: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 10005765
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 26, 2018
    Assignee: Capella Therapeutics, Inc.
    Inventor: Yun Long
  • BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170183330
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 29, 2017
    Applicant: Capella Therapeutics, Inc.
    Inventor: Yun LONG